NanoRepro (NN6.DE) Stock Price
NanoRepro Price
Revenue has compounded at 22.0% per year over the past 18 years to 4.65 M EUR. NanoRepro's net margin stands at -42.7%, down from 18.3% several years earlier. NanoRepro currently offers a dividend yield of about 9.40%. Analysts set a median price target of 4.59 EUR, implying 187.8% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
NanoRepro stock price
NanoRepro business model & stock analysis
Frequently asked questions about NanoRepro
The business model of Nanorepro AG, a leading healthcare company, focuses on the development and commercialization of innovative medical diagnostics. Nanorepro specializes in rapid, easy-to-use diagnostics for various medical conditions, including fertility, infectious diseases, allergies, and drug tests. With a strong emphasis on research and development, Nanorepro continuously expands its product portfolio to cater to the evolving healthcare needs of individuals and healthcare professionals worldwide. Through its cutting-edge technologies and strategic partnerships, Nanorepro aims to improve patient outcomes by providing accurate and timely diagnostic solutions.
Nanorepro AG is primarily active in the healthcare industry.
The main competitors of Nanorepro AG in the market include companies such as Abbott Laboratories, QIAGEN, Roche Diagnostics, and Thermo Fisher Scientific.
Nanorepro AG is a German biotechnology company specializing in the development and production of rapid diagnostic tests. Founded in 2006, Nanorepro AG has established itself as a leading player in the field, with a strong focus on innovative healthcare solutions. The company's core areas of expertise include infectious diseases, women's health, and drug testing. Nanorepro AG has a proven track record of delivering reliable and accurate diagnostic tools, empowering healthcare professionals and patients alike. With a commitment to quality and continuous research, Nanorepro AG is dedicated to improving global healthcare outcomes through advanced diagnostic solutions.
Nanorepro AG, a leading company in the healthcare sector, has achieved several significant milestones. The company successfully developed and launched innovative, easy-to-use medical self-tests, revolutionizing the point-of-care diagnostic market. Nanorepro AG demonstrated impressive revenue growth, expanding its market presence both domestically and internationally. The company's dedication to continuous innovation and research has resulted in the development of cutting-edge technologies, ensuring accuracy and reliability in its products. Nanorepro AG's commitment to customer satisfaction and commitment to quality has garnered recognition and trust from healthcare professionals and end-users alike. Overall, Nanorepro AG's achievements solidify its position as a key player in the healthcare industry.
Nanorepro AG, a leading company in the field of medical diagnostics, is primarily present in Germany and other European countries. With its headquarters in Marburg, Germany, Nanorepro AG focuses on developing and distributing innovative rapid testing kits for various health conditions. The company's market penetration extends across Europe, including countries such as Austria, Switzerland, France, Italy, Spain, and the United Kingdom. Nanorepro AG has also expanded its presence in select international markets, aiming to provide its cutting-edge diagnostic solutions globally.
Nanorepro AG represents values of innovation, quality, and customer satisfaction in the field of healthcare diagnostics. With a strong focus on research and development, Nanorepro AG aims to provide reliable and user-friendly diagnostic solutions to improve patients' lives. The company's corporate philosophy is centered around delivering accurate and efficient testing products that are accessible to a wide range of users. Nanorepro AG prioritizes continuous improvement and seeks to stay at the forefront of technological advancements in order to address emerging healthcare challenges. By consistently delivering cutting-edge technologies, Nanorepro AG has established itself as a trusted name in the diagnostics industry.
Analysts currently set an average price target of 4.59 EUR for the NanoRepro stock (median: 4.59 EUR), implying +187.8 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the NanoRepro stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect NanoRepro to generate revenue of 18.10 M EUR and earnings per share of -0.13 EUR.
The NanoRepro share (NN6.DE) is listed on 6 stock exchanges, including: XETRA (NN6.DE), Frankfurt (NN6.F), München (NN6.MU), Düsseldorf (NN6.DU), Hamburg (NN6.HM).
The Nanorepro AG is an established company in the development and marketing of rapid tests and diagnostics. The business model is based on the production of innovative and reliable medical products that meet the needs in the field of healthcare. The company is divided into three divisions: human medicine, veterinary medicine, and food analysis. In human medicine, Nanorepro AG offers a wide range of rapid tests for self-testing by patients. These rapid tests enable a quick and cost-effective diagnosis of infectious diseases such as HIV, Hepatitis C, and other sexually transmitted diseases. The range also includes fertility tests, self-tests for measuring allergies and cardiovascular diseases, as well as pregnancy tests. The tests are highly popular and sold worldwide under the name "all-in-one." In veterinary medicine, Nanorepro AG offers rapid tests for the diagnosis of animal diseases. The products include a wide range of tests targeting various diseases such as tuberculosis, rabies, brucellosis, and malaria. These tests can be used in animal clinics, animal laboratories, and veterinary practices and contribute to quick diagnosis and treatment. In food analysis, Nanorepro AG develops and distributes specialized test kits for testing food quality and safety. The products include various tests that can detect contamination by bacteria, chemicals, allergens, and genetically modified organisms (GMOs). The tests help ensure the quality and safety of food by detecting potential hazards early. Nanorepro AG is also engaged in research and development of new diagnostics. The company continuously invests in the development of new products to respond to the needs of healthcare and reduce treatment costs. Innovations, such as DNA tests for the identification of tumor mutations, have already been successfully developed and are available on the market. In summary, the business model of Nanorepro AG is focused on a high-quality and wide range of products. The different divisions offer innovative and reliable products for disease diagnosis and food analysis. The company constantly invests in research and development to improve the accuracy and reliability of its products and meet the needs of customers.
The expected revenue of NanoRepro is 18.10 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of NanoRepro is -1.69 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of NanoRepro is currently -11.90. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the NanoRepro stock.
The price-to-sales ratio (P/S) of NanoRepro is currently 1.11. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the NanoRepro stock.
The Eulerpool Quality Score for NanoRepro is 4/10.
The ISIN of NanoRepro is DE0006577109. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of NanoRepro is 657710. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of NanoRepro is NN6.DE. The ticker symbol is used to trade NanoRepro shares on the stock exchange.
NanoRepro stock
NanoRepro Peer Group
NanoRepro Ticker
NanoRepro FIGI
All fundamentals and in-depth analysis of NanoRepro
Our stock analysis for NanoRepro stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NanoRepro. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.